Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6038811 | 0.83 | MEN1 (0.55) | MEN1KMT2ASMN1; SMN2GAAMAPT | |
| SCHEMBL6039464 | 0.79 | MBTD1 (0.49) | MEN1KMT2ASMN1; SMN2MAPTEDNRA | |
| SCHEMBL6038633 | 0.78 | KMT2A (0.46) | MEN1KMT2AGAAMAPTEDNRA | |
| SCHEMBL6038688 | 0.77 | RAB9A (0.48) | MEN1KMT2ASMN1; SMN2GAAMAPT | |
| SCHEMBL6038958 | 0.77 | KDM4E (0.61) | MEN1KMT2AGAAMAPTHPGD | |
| SCHEMBL6038531 | 0.76 | MBTD1 (0.54) | MEN1KMT2A | |
| SCHEMBL6038954 | 0.76 | KMT2A (0.50) | MEN1KMT2ASMN1; SMN2LMNAHTT | |
| SCHEMBL6038605 | 0.75 | KMT2A (0.54) | MEN1KMT2ASMN1; SMN2GAAMAPT | |
| SCHEMBL6038918 | 0.75 | AR (0.49) | MEN1KMT2AGAAEDNRAALDH1A1 | |
| SCHEMBL6039178 | 0.75 | MEN1 (0.49) | MEN1KMT2ASMN1; SMN2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | MEN1 2431/4885KMT2A 4190/4885SMN1; SMN2 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.